RNAC Cartesian Therapeutics Inc
Price (delayed)
$12.95
Market cap
$335.5M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$4.48
Enterprise value
$136.87M
selecta biosciences, inc. is a clinical-stage biopharmaceutical company that is focused on unlocking the full potential of biologic therapies by mitigating unwanted immune responses. selecta plans to combine its tolerogenic
Highlights
The company's equity has surged by 98% YoY
The company's EPS has surged by 91% QoQ and by 91% YoY
RNAC's revenue is up by 50% year-on-year but it is down by 19% since the previous quarter
RNAC's gross profit is up by 50% YoY but it is down by 19% QoQ
The quick ratio is down by 12% QoQ
Key stats
What are the main financial stats of RNAC
Market
Valuations
Earnings
Shares outstanding
25.91M
Market cap
$335.5M
Enterprise value
$136.87M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
5.75
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.52
Revenue
$38.91M
Gross profit
$38.91M
Operating income
-$43.9M
Net income
-$77.42M
EBIT
-$77.14M
EBITDA
-$73.55M
Free cash flow
-$32.42M
Per share
Balance sheet
Liquidity
EPS
-$4.48
EPS diluted
-$4.49
Free cash flow per share
-$1.88
Book value per share
-$0.27
Revenue per share
$2.25
TBVPS
$22.39
Total assets
$435.02M
Total liabilities
$441.83M
Debt
$13.98M
Equity
-$6.8M
Working capital
$193.65M
Debt to equity
-2.06
Current ratio
9.43
Quick ratio
9.29
Net debt/EBITDA
2.7
Margins
Efficiency
Dividend
EBITDA margin
-189%
Gross margin
100%
Net margin
-199%
Operating margin
-112.8%
Return on assets
-19.8%
Return on equity
N/A
Return on invested capital
-44.4%
Return on capital employed
-18.7%
Return on sales
-198.2%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
RNAC stock price
How has the Cartesian Therapeutics stock price performed over time
Intraday
3.68%
1 week
-12.97%
1 month
-31.26%
1 year
-18.55%
YTD
-27.69%
QTD
-1.75%
Financial performance
How have Cartesian Therapeutics's revenue and profit performed over time
Revenue
$38.91M
Gross profit
$38.91M
Operating income
-$43.9M
Net income
-$77.42M
Gross margin
100%
Net margin
-199%
The company's net margin has surged by 76% YoY and by 61% QoQ
RNAC's net income has soared by 68% from the previous quarter and by 65% YoY
RNAC's operating margin has soared by 66% YoY
RNAC's revenue is up by 50% year-on-year but it is down by 19% since the previous quarter
Growth
What is Cartesian Therapeutics's growth rate over time
Valuation
What is Cartesian Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
5.75
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.52
The company's EPS has surged by 91% QoQ and by 91% YoY
The company's equity has surged by 98% YoY
RNAC's revenue is up by 50% year-on-year but it is down by 19% since the previous quarter
RNAC's P/S is 38% lower than its 5-year quarterly average of 9.0 and 20% lower than its last 4 quarters average of 6.9
Efficiency
How efficient is Cartesian Therapeutics business performance
Cartesian Therapeutics's ROIC has soared by 90% YoY and by 73% from the previous quarter
The return on assets has surged by 84% year-on-year and by 72% since the previous quarter
The company's return on sales has surged by 78% YoY and by 64% QoQ
Dividends
What is RNAC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for RNAC.
Financial health
How did Cartesian Therapeutics financials performed over time
Cartesian Therapeutics's total assets has increased by 43% YoY but it has decreased by 4.5% from the previous quarter
The quick ratio is down by 12% QoQ
Cartesian Therapeutics's debt to equity has plunged by 111% from the previous quarter
The company's equity has surged by 98% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.